214 related articles for article (PubMed ID: 20440754)
21. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
22. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):158-62. PubMed ID: 11133861
[TBL] [Abstract][Full Text] [Related]
23. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.
Wang Y; Xue SA; Hallden G; Francis J; Yuan M; Griffin BE; Lemoine NR
Cancer Res; 2005 Feb; 65(4):1523-31. PubMed ID: 15735041
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
25. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
Romanowski EG; Gordon YJ; Araullo-Cruz T; Yates KA; Kinchington PR
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
[TBL] [Abstract][Full Text] [Related]
27. Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro.
Ibrišimović M; Nagl U; Kneidinger D; Rauch M; Lion T; Klein R
J Gene Med; 2012 Jan; 14(1):3-19. PubMed ID: 22190534
[TBL] [Abstract][Full Text] [Related]
28. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
Hartline CB; Gustin KM; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
J Infect Dis; 2005 Feb; 191(3):396-9. PubMed ID: 15633099
[TBL] [Abstract][Full Text] [Related]
29. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
Gordon YJ; Araullo-Cruz TP; Johnson YF; Romanowski EG; Kinchington PR
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2774-8. PubMed ID: 8977495
[TBL] [Abstract][Full Text] [Related]
30. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model.
Toth K; Spencer JF; Dhar D; Sagartz JE; Buller RM; Painter GR; Wold WS
Proc Natl Acad Sci U S A; 2008 May; 105(20):7293-7. PubMed ID: 18490659
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
de Oliveira CB; Stevenson D; LaBree L; McDonnell PJ; Trousdale MD
Antiviral Res; 1996 Jul; 31(3):165-72. PubMed ID: 8811201
[TBL] [Abstract][Full Text] [Related]
32. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
33. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.
Romanowski EG; Yates KA; Gordon YJ
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5295-9. PubMed ID: 19516011
[TBL] [Abstract][Full Text] [Related]
34. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
35. Oral USC-093, a novel homoserinamide analogue of the tyrosinamide (S)-HPMPA prodrug USC-087 has decreased nephrotoxicity while maintaining antiviral efficacy against human adenovirus infection of Syrian hamsters.
Tollefson AE; Riemann SB; Ying B; Spencer JF; Overhulse JM; Kashemirov BA; Wold WSM; McKenna CE; Toth K
Antiviral Res; 2024 Feb; 222():105799. PubMed ID: 38190973
[TBL] [Abstract][Full Text] [Related]
36. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).
Ouchi M; Kawamura H; Urata Y; Fujiwara T
Invest New Drugs; 2009 Jun; 27(3):241-5. PubMed ID: 18754077
[TBL] [Abstract][Full Text] [Related]
37. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Romanowski EG; Yates KA; Teuchner B; Nagl M; Irschick EU; Gordon YJ
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2021-6. PubMed ID: 16639011
[TBL] [Abstract][Full Text] [Related]
38. Antiviral activity of cidofovir and ribavirin against the new human adenovirus subtype 14a that is associated with severe pneumonia.
Darr S; Madisch I; Heim A
Clin Infect Dis; 2008 Sep; 47(5):731-2. PubMed ID: 18680401
[No Abstract] [Full Text] [Related]
39. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
40. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
Thomas MA; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
